A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT07098338 · readout in 960 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
278estimated
Sites
83
Countries
Australia, Canada, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-07 | actual | When the study began enrolling |
| Primary completion | 2029-04-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Ramucirumab — also filed as Cyramza
- Drug: Dato-DXd — also filed as DS-1062
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AE) and serious adverse events (SAE)
measured Through study completion, an average of 3 years
Objective response rate (ORR)
measured Through study completion, an average of 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed